K-ras gene mutation+2
RecruitingStudy of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer
Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer
- Disease:K-ras gene mutationNon-small cell lung cancer+1
- Substances:BudesonideCarboplatin+4
Hungary- Participants:18–64 years · 65+ years
- Substances:Budesonide
- Sponsor:F. Hoffmann-La Roche AG














